A large multinational study tracking more than 460,000 people with ADHD across five health care systems has found that the period of highest risk for self-harm is the three months before medication treatment begins, not after. The research, led by Aston University scientists and published in BMJ Mental Health, counters long-standing fears that ADHD drugs themselves drive self-harm behavior.
What the data showed
Researchers, led by Dr. Adrienne Chan and Regius Professor Ian Wong at Aston Pharmacy School, examined health records from Hong Kong, New Zealand, South Korea, Taiwan and the United Kingdom, covering people who started ADHD medication and had a documented history of self-harm between 2001 and 2020. The team compared three windows: the 90 days before treatment, the first 90 days of treatment, and the period afterward, against times when patients were not on medication.
In every one of the five health care systems studied, self-harm risk was highest in the 90 days immediately preceding treatment. Risk remained somewhat elevated after medication started but dropped well below pre-treatment levels. The consistency of this pattern across different countries and health systems led the authors to conclude that ADHD medication is not the primary driver of self-harm risk.
Why the findings matter for care
The study's authors frame the pre-treatment spike as a signal for earlier clinical attention rather than a reason for caution about medication itself. "People often worry that ADHD medication itself increases the risk of self-harm. What our findings suggest is that many people are already at their highest risk before treatment even begins," Chan said. "This highlights an important opportunity for earlier intervention."
The research team suggests that clinicians and families should watch closely for worsening symptoms in the lead-up to a diagnosis or treatment decision, since this appears to be when people are most vulnerable-well before any prescription is written.
A platform for further research
The project drew on collaborators from UCL, the University of Hong Kong, the University of Auckland, Sungkyunkwan University, National Cheng Kung University, Seoul National University, the University of Melbourne, Rutgers University, the University of Waterloo, the Chinese University of Hong Kong and Macau University of Science and Technology. Each country's patient data stayed within its own health system, with researchers applying a shared analytical method-an approach Wong described as combining international collaboration with strict data governance.
The team says this infrastructure will now be used to study other questions, including what happens when patients stop or restart ADHD medication, and whether ethnicity or socioeconomic disadvantage shapes disparities in ADHD treatment access and outcomes across these health systems. As with any observational study, the findings describe patterns in large populations and do not establish what drives risk for any single individual; people with concerns about ADHD treatment should discuss them with a qualified health care provider.